MoonLake Immunotherapeutics, (MLTX) News
Filter MLTX News Items
MLTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MLTX News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest MLTX News From Around the Web
Below are the latest news stories about MOONLAKE IMMUNOTHERAPEUTICS that investors may wish to consider to help them evaluate MLTX as an investment opportunity.
MoonLake Immunotherapeutics price target raised to $81 from $71 at BTIGBTIG raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $81 from $71 and keeps a Buy rating on the shares. The firm expects sonelokimab’s “differentiating features to translate to best-in-class efficacy in axial spondyloarthritis, palmoplantar pustulosis, and hidradenitis suppurativa. These are severe diseases with high unmet need, the analyst tells investors in a research note. BTIG says the axial spondyloarthritis market is expected to exceed $10B by the mid-2030s and note |
MoonLake's Three New Trials Will Expand Sonelokimab's Potential, Wedbush SaysMoonLake Immunotherapeutics' (MLTX) three new studies of the company's nanobody sonelokimab in three |
MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimabNew trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 LEDA trial in palmoplantar pustulosis (PPP) and Phase 2 S-OLARIS trial in axial spondyloarthritis (axSpA)MoonLake now independently running seven trials in 2025 across large dermatology and rheumatology indications: adult HS, adolescent HS, psoriatic arthritis (PsA), PPP and axSpAPhase 2 and Phase 3 data read-outs across all target i |
Is There An Opportunity With MoonLake Immunotherapeutics' (NASDAQ:MLTX) 27% Undervaluation?Key Insights MoonLake Immunotherapeutics' estimated fair value is US$73.93 based on 2 Stage Free Cash Flow to Equity... |
MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritisMoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis Two trials for active psoriatic arthritis (PsA) with one focusing on biologic-naïve patients and including evaluation of radiographic progression (IZAR-1), and the other focusing on TNF-IR patients while being the first trial to include risankizumab as an active reference arm (IZAR-2)Program will evaluate sonelokimab for a total of 52 weeks, across IZAR-1 and IZAR-2, a |
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business UpdateMoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update Ended the third quarter with $493.9 million in cash, cash equivalents and short-term marketable debt securities, expected to support a roadmap rich in potential catalysts and a cash runway to the end of 2026Strong market performance of other IL-17 inhibitors in hidradenitis suppurativa (HS) and other inflammatory indications validating large market opportunity for sonelokimabPhase 3 clinical p |
Biotechnology Value Fund L.P. Reduces Stake in MoonLake ImmunotherapeuticsOn October 4, 2024, Biotechnology Value Fund L.P. executed a significant transaction involving the shares of MoonLake Immunotherapeutics (NASDAQ:MLTX). Following this transaction, Biotechnology Value Fund L.P. now holds a total of 19,751,284 shares in MoonLake Immunotherapeutics, representing 31.40% of their total portfolio. |
Is MoonLake Immunotherapeutics (MLTX) the Best Guru Stock To Buy Now?We recently compiled a list of the 10 Best Guru Stocks To Buy Now. In this article, we will have a look at where MoonLake Immunotherapeutics (NASDAQ:MLTX) ranks among the best guru stocks to buy now. Due to the plethora of investment options such as equities, bonds, and mutual funds that are available today, picking […] |
MoonLake Immunotherapeutics (MLTX): Short Seller Sentiment is Bearish On This ADR StockWe recently compiled a list of the 10 Worst ADR Stocks To Buy According to Short Sellers. In this article, we are going to take a look at where MoonLake Immunotherapeutics (NASDAQ:MLTX) stands against the other ADR stocks. An American Depositary Receipt (ADR) is a certificate issued by a U.S. bank that represents shares of a […] |
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11MoonLake Immunotherapeutics to host a Capital Markets Updateon Wednesday, September 11 ZUG, Switzerland, September 9, 2024 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host a Capital Markets Update for investors and analysts live from New York on Wednesday, September 11 from 2024, from 9:00 – 10:30 EST/06:00 – 08:30 PST/14:00 – 16:30 CETThe event will provide business u |